

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
<p>*Note about the savings forecast:</p> <ul style="list-style-type: none"> ▷ The savings forecast involved calculating a volume reduction of 3% across all programs for one financial year. They are tentative estimates only and do not account for external factors such as pricing changes and environmental effects such as COVID-19. ▷ For further information refer to program specific formative research reports and evaluation plans. ▷ The cost benefit of reduced hospitalisation secondary to adverse events (in relevant programs) is not included in this initial forecasting. This forecasting would be undertaken subject to an individual workplan. ▷ Total program savings are reported annually to the department per grant agreement. 							
SCHEDULE 4 - OPERATIONAL SERVICES AND GOVERNANCE	Schedule 4	Operational Services and Governance	To ensure required levels of transparency, efficiency and accountability in the execution of responsibilities as stewards of quality use of medicines in Australia through focused management of the Grant Agreement.	<ul style="list-style-type: none"> • To effectively administer and manage the grant agreement and ensure all performance indicators, targets, milestones and deliverables are tracked. • Work towards Corporate structure and operational arrangements in line with recommendations from the Review of Quality use Medicines Program delivery by NPS MedicineWise (The Review). • To support internal organisational culture change program by building financial, agreement / contract management and reporting capability, and consumer centricity and QUM collaborations. 	\$5,958,593		Australian Government Department of Health
SCHEDULE 5 - QUM GOVERNMENT PRIORITIES	Schedule 5A	QUM Health Technologies Topic Selection	<p>To drive quality use of medicines and health technologies across the Australian healthcare landscape and improve health outcomes through the identification of QUM priority areas for stewardship and future programs and activities that:</p> <ul style="list-style-type: none"> • Address areas of unmet need • Are evidence based • Aim to reduce medication misuse and improve health literacy • Have potential to contribute to health system efficiencies including the MBS and PBS • Support a collaborative and collective impact approach 	<ul style="list-style-type: none"> • Understand the QUM and health technology priorities of The Commonwealth and other key stakeholders. • Understand the existing services and programs in the QUM ecosystem and ensure activities are complementary as appropriate. • Apply an evidence-based research approach combined with stakeholder engagement and expert knowledge to identify priority issues. • Identify opportunities for programs to be developed, implemented and/or measured in partnership in order to maximise impact, avoid duplication, and provide value for money. • Identify programs that recognise and address emerging challenges related to ageing populations and complexity of managing people with co-morbidities and multiple medications. • Identify QUM priorities that require systems-based interventions. • Identify opportunities to demonstrate impact through: <ul style="list-style-type: none"> ○ Savings to the PBS and MBS ○ Improved health or economic outcomes ○ Reduced medication or other health technology mis-use ○ Improved consumer health literacy as relates QUM and health technologies ○ Cross-sector QUM-related activities 	\$451,809		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
	Schedule 5C	Remote Area Aboriginal Health Service program	To ensure a safe and effective QUM approach to the provision of medicines to residents of remote Aboriginal and Torres Strait Islander communities under the RAAHS program.	<ul style="list-style-type: none"> Development of high quality and relevant education that is provided to all health professionals who may order, stock and supply PBS medicines under the RAAHS program. Development of guidance that takes into account the State/Territory or other relevant workforce or medicines protocols. To maximise leverage of existing resources to ensure they provide value for money and avoid unnecessary duplication. Employ effective stakeholder engagement to ensure a whole of setting approach in order to maximise uptake and impact. 	\$91,363		Australian Government Department of Health
	Schedule 5D	Clinical Intervention Advisory Group (CIAG)	<p>The Clinical Intervention Advisory Group (CIAG) supports NPS MedicineWise to deliver against Grant Agreement objectives through the provision of strategic advice on potential and current Quality Use of Medicines (QUM) Grant programs, products and services in order to:</p> <ul style="list-style-type: none"> Ensure that QUM programs address unmet needs as identified through engagement with the relevant stakeholders Improve medicine and medical test decisions by health professionals and/or consumers Ensure that NPS MedicineWise is able to deliver innovative approaches to program delivery. 	<p>To provide advice on the following :</p> <ul style="list-style-type: none"> Program and activity selection: including current quality use of medicines or medical tests issues of high unmet need, relevant settings and target audiences and opportunities (including partnerships) Program and intervention design and effectiveness to support behaviour change programs: drawing from implementation science, social marketing, behavioural economics, and human centred design Program scope: assisting with development of clear program objectives and key messages Evaluation: advice on appropriate evaluation methodologies and questions Opportunities for innovation that deliver on Grant initiatives, including, but not limited to, reach to specialists and support for PBS/MBS sustainability. To support exploration of different methods to engage stakeholders in creating opportunities for collective impact. External activities that may impact on QUM activities. 	\$100,766		Australian Government Department of Health
SCHEDULE 6 - QUM FOR HEALTH PROFESSIONALS AND CONSUMERS	Schedule 6A	Asthma Educational Program	<p>Improve the diagnosis and management of people with asthma in Australian primary care</p> <p>Improve health literacy of target audience as it relates to asthma management</p> <p>Reduce misuse of medicines and other health technologies as relates to asthma management.</p> <p>Deliver PBS savings as relates to relevant asthma medications in line with program objectives.</p>	<ul style="list-style-type: none"> Deliver a national multi-faceted evidence-based behaviour change initiative and education service on quality use of medicines and related health technologies (spirometry) as relates to asthma management Implement behavioural change interventions to address quality use of medicines (QUM) issues and practice gaps in paediatric asthma Provide education on guideline and regulatory changes regarding adolescent and adult asthma, management to assist health professionals in the appropriate implementation of new models of asthma management in their practice Work in collaboration with key stakeholder organisations to maximise impact and avoid unnecessary duplication 	\$1,960,282	PBS \$0.85M Evaluation method: Interrupted time series	Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
	Schedule 6B	Opioids Educational Program	<p>To improve quality use of opioids and reduce harms for Australians with chronic non-cancer pain (CNCP) who are managed in primary care.</p> <p>Improved health literacy as relates to opioid use.</p> <p>Deliver PBS savings as relates to relevant opioid medicines in line with program objectives.</p>	<ul style="list-style-type: none"> Deliver a nationally delivered evidence-based behaviour change program which aims to improve quality use of opioids and reduce harms for Australians with chronic non-cancer pain (CNCP). Increase GP knowledge and awareness as relates to quality use of opioids for management of CNCP Work in collaboration with key stakeholder organisations to maximise impact and avoid unnecessary duplication. 	1,061,535	PBS \$7.9M Evaluation method: Interrupted Time Series	Australian Government Department of Health
	Schedule 6C	Psychotropics in Aged Care	<p>To improve the management of behavioural and psychological symptoms (BPSD) of dementia in people aged ≥ 65 years.</p>	<ul style="list-style-type: none"> Deliver a national, independent, evidence-based, behaviour change initiative and education services on quality use of medicines in people with dementia aged ≥ 65 years. Decrease inappropriate prescribing of psychotropic medicines (i.e. antipsychotics and benzodiazepines) for people with dementia aged ≥65 years living in residential aged care facilities and the wider community. Increase health professional knowledge of evidence-based non-pharmacological approaches to manage dementia in people aged ≥ 65 years. Increase the health literacy of carers regarding psychotropic medicines and non-pharmacological approaches used in the management of dementia in people aged ≥ 65 years. Increase the proportion of health professionals who seek to identify the underlying causes of behaviour in people with dementia aged ≥ 65 years to inform appropriate management. 	3,382,599	PBS \$1.3M Evaluation method: Interrupted Time Series	Australian Government Department of Health
	Schedule 6D	Imaging for Lower Gastrointestinal Disorders	<p>To improve quality use of imaging for Australians with lower gastrointestinal disorders who are managed in primary care.</p> <p>Reduce the misuse of imaging as relates to lower gastrointestinal disorders.</p> <p>Provide independent, evidence-based information, behaviour change initiatives and education services on quality use of medicines and diagnostics.</p> <p>Deliver MBS savings as relates to use of imaging for lower gastro-intestinal disorders in line with program objectives.</p>	<ul style="list-style-type: none"> Improve knowledge and management of people with lower gastrointestinal disorders as measured by reduction in inappropriate use of CT scan and ultrasound services for lower gastrointestinal disorders in line with program objectives. Reduce inappropriate GP referral rates for CT scan and ultrasound services of the lower abdomen 	\$47,191	MBS \$1.12M Evaluation method: Interrupted Time Series	Australian Government Department of Health
	Schedule 6E	Good Medicine Better Health program	<p>To improve Aboriginal and Torres Strait Islander Health Workers and Practitioners' (including Remote Area Aboriginal Health Services (RAAHS) workers) knowledge, skills and access to resources in quality use of medicines (QUM)</p> <p>Provide education that builds the competency and confidence of Aboriginal and Torres Strait Islander Health Workers (AHW) and Practitioners in the</p>	<ul style="list-style-type: none"> Increase awareness of QUM among Aboriginal and Torres Strait Islander communities through the education of Aboriginal and Torres Strait Islander Health Workers and Practitioners Work in partnership with Aboriginal and Torres Strait Islander organisations, including National Aboriginal Community Controlled Health Organisation (NACCHO) and National Aboriginal and Torres Strait Islander Health Workforce Association (NATSIHWA) to ensure that the program meets the needs of the diversity of health providers serving Indigenous people. 	\$212,402		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
			<p>quality use of medicines and medical tests.</p> <p>Enable access to best resources to improve medicines literacy of Aboriginal and Torres Strait Islander communities.</p>	<ul style="list-style-type: none"> • Provide a flexible program that allows for adaptation to local communities. • Incentivise participation by alignment of QUM online education with continuing professional development (CPD) and training requirements of Aboriginal and Torres Strait Islander Health Workers and Practitioners • Provide consumer resources for AHW use to support improved QUM health literacy with consumers. • Build and strengthen partnerships with the wider health sector that create opportunities for AHWs to play a broader role in QUM. • Work in partnership with key stakeholders to measure program impact. 			
	Schedule 6F	National Prescribing Curriculum (NPC)	This program aims to improve health literacy and medication confidence among undergraduate and early-career health professionals as relates to QUM principles through building improved health literacy and medication confidence amongst undergraduate and early career prescribers through the ongoing support of the National Prescribing Curriculum.	<ul style="list-style-type: none"> • Provide and maintain independent, interactive evidence-based education services on quality use of medicines to support undergraduate prescribers (National Prescribing Curriculum). • Provide a learning experience that increases user health literacy (as relates to QUM) and confidence in prescribing and communication using: <ul style="list-style-type: none"> ○ real life situations in hospital and general practice settings. ○ complex, authentic tasks, for example completing prescriptions for medicines. ○ feedback from experts, and for right and wrong answers. ○ links to current evidence-based resources including QUM grant publications, Therapeutic Guidelines and Australian Medicines Handbook. ○ Incorporation of Choosing Wisely recommendations and principles • Increased proportion of medical and pharmacy schools participating in the program through targeted promotion and marketing. 	\$187,409		Australian Government Department of Health
	Schedule 6G	Outcomes Evaluation	<p>The Grant Agreement requires that programs and activities are evaluated in order to demonstrate impacts and outcomes that support quality use of medicines and health technologies in Australia. This work plan supports activities that will demonstrate impact of programs on activities on:</p> <ul style="list-style-type: none"> ○ Misuse of medicines and other health technologies ○ Health Literacy as relates to Quality Use of Medicines ○ Health and economic outcomes ○ Sustainability of the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule 	<ul style="list-style-type: none"> • Comprehensive evaluation of all multi-facetted, national and regional programs funded under the QUM grant in order to demonstrate improvements in Quality Use of Medicines and health technologies • Enable assessment of QUM programs with respect to value for money • Support the selection of Topics for future programs and activities that will deliver on required program outcomes through the provision of cost savings forecasts reports and other feasibility assessments as required • Utilisation of relevant and multiple data sets to demonstrate program outcomes • Development and measurement of indicators to support measurement of QUM stewardship activities • Demonstrate collective impact of multi-disciplinary QUM programs delivered in partnership • Use of robust evaluation methodologies that have been agreed with The Commonwealth • Provision of evaluation reports (in line with the Grant Agreement). 	\$775,636		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
	Schedule 6H	Program and Intervention Innovation	<p>To assess the effectiveness and value for money of existing interventions and program models,</p> <p>Develop contemporary, evidence-based understanding of best practice behaviour change in QUM,</p> <p>Utilise MedicineInsight to show the effectiveness of program interventions.</p>	<ul style="list-style-type: none"> Review of existing intervention suite and program delivery model. Continually innovate retained interventions. Pilot additional new and innovative QUM grant interventions and program models. Evaluate interventions to understand their relative effectiveness within and across QUM grant programs and clinical areas. Dissemination of information across the health sector that supports the design of activities to support a QUM collective impact approach. 	\$125,366		Australian Government Department of Health
	Schedule 6I	Medication Safety Evidence Review of Risk Assessment Tools	Reduced misuse of medicines through a reduction in medicine burden for patients and related adverse medicine events.	<p>To increase clinician access to tools that enable them to assess medicine safety and manage the risk of adverse medicine events by:</p> <ul style="list-style-type: none"> consulting with subject matter experts regarding key tools to measure risk of medication safety and needs of prescriber and pharmacist audiences with respect to these tools undertaking a desktop evidence review of a prioritised list of key tools to assist in measurement of the risk of medication safety and identification of patients at high risk identification of key prioritised tools and their utility, accessibility, risks and benefits based on the stakeholder consultation and desktop review. Tools will be prioritised based on their potential for impact, useability and wider scale implementation. providing clear recommendations on implementation to increase access and awareness of the prioritised tools including consideration of integration within current and future NPS MedicineWise programs of work (for example, Aged Care Program). Based on further consultation with the Department this could include: <ul style="list-style-type: none"> publishing prioritised tools on the NPS MedicineWise website to facilitate dissemination and access (subject to permissions) promotion to member organisations and key stakeholders in QUM support for specific research studies to increase the evidence base in this space. 	\$67,567		Australian Government Department of Health
	Schedule 6J	MedicineWise APP	<p>To support improved health literacy and reduced medicines misuse by providing consumers with useful medicines management tools and information that support self-medicine-management, adherence, and safe use.</p> <p>Actively promote the MedicineWise app in line with recommendation 23 of The Review of the Quality Use of Medicines Program's Delivery by the National Prescribing Service Limited (NPS MedicineWise) Report (The Review).</p>	<ul style="list-style-type: none"> Deliver personalised medicines information in line with key Quality Use of Medicines (QUM) issues Increase consumer and health professional uptake through effective promotion and partnering Increase the level of tailored content and useful health and medicines information available through new content and content-sharing partnerships Increase app user retention by providing a valuable health and medicine platform that is valued by users 	\$636,071		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
	Schedule 6K (i)	Consumer Engagement Plan	Grant programs and activities are influenced by Australian consumers throughout from planning, design, and implementation, to evaluation, to improve the quality use of medicines, lower medicine misuse and build health literacy.	Implement an effective consumer engagement plan that will: <ul style="list-style-type: none"> Identify issues consumers face using medicines and design enhanced models of care which address those issues improve the quality and suitability of products and services to a diverse range of consumers' needs generate new and innovative ideas for quality use of medicines campaigns and programs produce health information that is understandable which promote better use of medicines in line with quality use of medicines principles. 	\$449,471		Australian Government Department of Health
	Schedule 6K (ii)	Consumer Segmentation	This will contribute to improving consumer health literacy as it relates to QUM through the implementation of research to: <ul style="list-style-type: none"> Understand the current status of health literacy amongst Australians Inform future Grant activities Support the Review of the National Medicines Policy. 	<ul style="list-style-type: none"> Provide findings that reflect the knowledge, attitudes and perceptions of 'grass roots consumers' in relation to QUM Identify the current understanding of consumer health literacy for Australians as it relates to QUM Identify and characterise key consumer segments as they relate to QUM health literacy to assist in future resource or program development Provide recommendations for resource/program development to meet unmet needs Identify relevant QUM and health literacy indicators for future evaluation of collective impact e.g. Consumer Segmentation Survey to measure QUM awareness and health literacy Distribute findings to support the review of the National Medicines Policy and integrate into other Grant activities. 			Australian Government Department of Health
	Schedule 6L	RACGP CPD Accreditation	To support improved prescriber behaviour and reduce inappropriate prescribing and use of health technologies by General Practitioners by ensuring that educational activities developed under the Grant Agreement meet registration requirements for continuing professional development.	<ul style="list-style-type: none"> Incentivise GP participation in NPS MedicineWise educational activities through appropriate accreditation with RACGP NPS MedicineWise educational programs are available through the RACGP CPD program for General Practitioners NPS MedicineWise personnel are skilled in the requirements for meeting relevant CPD education standards of RACGP. 	\$40,000		Australian Government Department of Health
	Schedule 6M	Prescribing Competencies Framework	Support the judicious, safe and appropriate prescribing of medicines in Australia through sector-wide uptake of the National PCF.	<ul style="list-style-type: none"> Facilitate sector-wide engagement through a formal public consultation process Publication and promotion of a refreshed National PCF Integration of National PCF principles into standards, education and training 	\$35,464		Australian Government Department of Health
	Schedule 6N	Heart Failure	Delivery of a national educational program that aims to improve the quality use of medicines and health technologies in the management of heart failure (HF).	<ul style="list-style-type: none"> Improve the quality use of medicines for patients with heart failure in primary care and transitions of care (i.e. from hospital to community). Improve health outcomes for patients with heart failure (i.e. reduce the incidence of preventable hospitalisation). 	\$1,327,731	Health Outcomes study Evaluation method: Utilising linked data to evaluate hospitalisation rates	Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
				<ul style="list-style-type: none"> Improve the quality use of tests in the diagnosis and management of patients with heart failure in primary care. Increase health professional knowledge of evidence-based diagnosis and management of heart failure. Increase the health literacy of patients with heart failure in management of their condition. 		Economic evaluation	
SCHEDULE 7 - QUM STEWARDSHIP AND AWARENESS PROGRAM	Schedule 7A	Choosing Wisely Australia	<p>To promote and support a national conversation about unnecessary tests, treatments and procedures.</p> <p>Improve health literacy as it relates to unnecessary tests, treatments and procedures</p> <p>Reduce unnecessary use of tests, treatments and procedures.</p>	<ul style="list-style-type: none"> Change clinician and consumer attitudes to the use of unnecessary tests, treatments and procedures Foster consumer awareness and engagement of key messages and principles Demonstrate positive change in clinical practice to reduce the unnecessary use of tests, treatments and procedures Promote alignment within the QUM system, i.e. integration into training, guidelines and policy. 	\$640,809		Australian Government Department of Health
	Schedule 7B	Digital and Direct Communications Platform	To provide and support a reliable digital platform for consumers and health professionals that hosts products and services that support quality use of medicines and health technologies.	<ul style="list-style-type: none"> Use data to distribute and send updates/alerts to NPS MedicineWise publication subscribers (eg Australian Prescriber) Maintain relationships with key stakeholders, including health professionals through digital and direct communications Provide a platform to register and engage in continuing professional development (CPD) activities Increase health professional participation in CPD education activities Ensure continual accessibility of QUM information is available across platforms 	\$1,493,567		Australian Government Department of Health
	Schedule 7C	Digital Content	<p>Ensure contemporary, high-quality and up-to-date information to support the principles of quality use of medicines (QUM)/health technologies among consumers, their carers and health professionals in the Australian context.</p> <p>Support adult learning principles for reflective learning and behaviour change.</p>	<ul style="list-style-type: none"> Provide and maintain evidence-based QUM/health technologies information and education that is up-to-date for health professional and consumer audiences Maintain continuing professional development (CPD) accreditation for relevant activities as an incentive for participation Maintain timely up-to-date content in line with relevant Government priorities and policy changes Contribute to improving health literacy of Australians. 	\$491,676		Australian Government Department of Health
	Schedule 7D	National Medicine Symposium	Support a national dialogue on quality use of medicines (QUM) through multi-disciplinary, multi-sectorial forums that support and promote quality use of medicines and health technologies	<ul style="list-style-type: none"> Host the annual National Medicines Symposium – a national forum dedicated to quality use of medicines and health technologies Engage key stakeholders in agenda setting (ie Commonwealth, PHNs, RACGP and ACSQHC) to ensure program reflects sector priorities Facilitate cross-sector collaborations and partnerships that support a collective impact approach to promote quality use of medicines and health technologies. Attendance by key stakeholders of the National Medicines Policy 	\$173,427		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
	Schedule 7E	Opioids Hospital Stewardship	Reduced misuse of medicines in the hospital setting due to inappropriate prescribing of opioids.	<ul style="list-style-type: none"> Provide a framework for introducing opioid stewardship and associated quality improvement activities to acute care settings. Enable an effective Opioids Stewardship program across state jurisdictions that leverages existing resources and established networks and engages key stakeholders in co-design, implementation and evaluation. Support patient education, and improved communication between transitions of care Demonstrate reduced inappropriate opioids prescribing. 	\$47,057		Australian Government Department of Health
	Schedule 7F	Council of Therapeutic Advisory Groups (CATAG)	<p>To provide insight into key quality use of medicines issues in the acute care sector and at transitions of care.</p> <p>Reduce misuse of medicines as relates to high cost medicines use in acute care.</p> <p>Influence medication safety as medicines enter the medicines management cycle.</p>	<ul style="list-style-type: none"> Provide, expert, consensus-based collaborative advice and advocacy for the purpose of maximising influence on medicines policy and practice to ensure a quality use of medicines approach is applied across local, state and national policy and practices. To increase equity of patient access to safe, cost-effective and affordable medicines nationally through the development of resources to guide decision-making processes at the local and jurisdictional levels. 	\$132,729		Australian Government Department of Health
SCHEDULE 8 - OPERATION AND DEVELOPMENT OF MEDICINEINSIGHT PROGRAMS	Schedule 8A	MedicineInsight Maintenance	MedicineInsight continues to be a robust, valuable and trusted national primary care data set that supports provision of post market surveillance and utilisation of data.	<ul style="list-style-type: none"> Maintenance of a minimum number of 500 participating general practices through proactive and regular engagement with participating practices Ensure stakeholder trust in MedicineInsight through maintenance and oversight of best practice data governance processes and ethics frameworks Increase awareness of MedicineInsight data and its application through publication of data quality and insights Ensure MedicineInsight remains viable, contemporary and compatible with new, emerging and changing technologies through ongoing maintenance and sector engagement 	\$2,815,904		Australian Government Department of Health
	Schedule 8B	MedicineInsight Data Linkage	To enhance the functionality of MedicineInsight to support post market surveillance activities and to support health outcome studies for evaluation of programs through data linkage to external data sets	<ul style="list-style-type: none"> Deliver a preferred linkage capability that can be used across the whole dataset. Demonstrate the success of the preferred linkage capability to connect MedicineInsight with external data sets. Analysis of linked data sets that may enable improved post market utilisation, surveillance data and health outcome studies. 	\$306,707		Australian Government Department of Health
	Schedule 8C	MedicineInsight Data Validation	Ensure that MedicineInsight accurately reflects general practice data and to ensure production of high quality post market surveillance reports.	<ul style="list-style-type: none"> In consultation with The Commonwealth, identify current gaps in MedicineInsight general practice data, prioritise data validation activities in line with Commonwealth priorities publication of data validation reports in line with Commonwealth priorities. 	\$119,429		Australian Government Department of Health
	Schedule 8E	MedicineInsight Independent Review and Evaluation	Following 10 years of continual funding under the QUM Grant Agreement, an independent review and evaluation of MedicineInsight has been commissioned.	<p>To determine:</p> <ul style="list-style-type: none"> Whether the objectives of the MedicineInsight program have been met 	\$118,334		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
				<ul style="list-style-type: none"> The benefits that MedicineInsight has delivered to the Quality Use of Medicines Grant program The value for money of the MedicineInsight program to the Australian Government Department of Health Future opportunities for MedicineInsight and how these might be best realised. 			
SCHEDULE 9 - POST MARKET INFORMATION AND DISSEMINATION PROGRAMS	Schedule 9A	MedicineInsight Post Market Surveillance	Improved post-market surveillance through the provision of data insights that provide policy-makers, regulators and other government agencies with timely and useful information on use of medications and health technologies in Australia, both at the national and local level.	<ul style="list-style-type: none"> Provision of regular MedicineInsight reports with up-to-date information that address areas of interest as specified by the Commonwealth. Development and delivery of a strategic plan that: <ul style="list-style-type: none"> clearly articulates the place of MedicineInsight in supporting post-market surveillance activities; identifies gaps, barriers and threats to the ability of MedicineInsight to support the needs of policy-makers and regulators; and identifies strategies and measures that can be taken to overcome these gaps, barriers and threats. Increased capability of MedicineInsight to support post-market surveillance activities for policy makers, regulators and other government agencies. Publication of approved MedicineInsight data insights in peer reviewed journals. 	\$516,782		Australian Government Department of Health
	Schedule 9B	MedicineInsight Data Collection from Specialists	To support improved post market surveillance through use of specialist prescribing insights	<ul style="list-style-type: none"> Assess the feasibility of collecting specialist data from specialist clinical information systems (CIS) into MedicineInsight. This will include: <ul style="list-style-type: none"> Engagement with, and identification of specialist practices suitable to participate in data collection Identification of any governance changes and dependencies required Ensuring specialist awareness of intent to collect data Undertake a pilot program to assess the feasibility of using data from specialists (private practice) Provide a feasibility report on collected specialist data and its potential to inform quality use of medicines (QUM) activities. 	\$ 151,728		Australian Government Department of Health
	Schedule 9C	Australian Prescriber	To provide independent evidence-based information for health professionals on drugs, therapeutics and health technologies in the Australian context.	<ul style="list-style-type: none"> Produce and disseminate regular and timely publications Provide publications that contain critical commentary on drugs and therapeutics for health professionals including post market use Leverage post market surveillance insights (where appropriate) to highlight issues relating to Quality Use of Medicines (QUM) and health technologies Prioritise emerging issues and high QUM/health technology needs. Increase the number of subscribers to Australian Prescriber communications. 	\$859,218		Australian Government Department of Health

QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES FY2020-21							
FY2020-2021 Activity Program Schedule	Grant ID	Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2020-21	Anticipated Savings and Impacts on PBS and MBS* (if applicable)	Funding Source
	Schedule 9D	Communication Policy	To increase awareness of new and emerging issues relating to medicines and health technologies in order for health professionals and consumers to make evidence-based decisions about the medicines and other health technologies.	<ul style="list-style-type: none"> Provide critical information on evidence relating to new or amended MBS, PBS and TGA listings Provide information that is clinically relevant and contextualised in order to best influence clinical practice Provide information that is timely, independent, evidence-based and developed using a robust clinical review process Deliver (as required) consumer information that is clear in language, accessible for all levels of ability, adheres to health literacy principles and supports person centred care Provide communications on policy changes that arise during the contract period and are identified by The Department as requiring additional and supporting content to be developed Promote publications to health professionals, stakeholders and consumers as appropriate. Work collaboratively with the Commonwealth in a review of RADAR to identify and determine an efficient and effective means of informing pharmacists and prescribers regarding PBS listings. 	\$308,181		Australian Government Department of Health
	Schedule 9E	Review of PBS Medicines for the Drug Utilisation Sub Committee (DUSC)	To contribute to the assessment of appropriate usage of medicines listed on the PBS through the analysis of medicines usage using MBS and PBS data and MedicineInsight data (as appropriate).	<ul style="list-style-type: none"> Provide a medicine utilisation report on PBS listed medicines for each DUSC meeting to be conducted between October 2020 to February 2022. The reviews will examine patterns of use, including quality use of medicines issues, and PBS expenditure 	\$356,253		Australian Government Department of Health
SCHEDULE 10 - PHONE LINE SERVICE PROGRAM	Schedule 10A	Medicine Line Service	To improve consumer knowledge of quality use of medicines and other health technologies and promote medication safety.	<ul style="list-style-type: none"> Provision of a communications service to increase awareness of QUM principles and practices for consumers. To encourage consumer reporting of Adverse Drug Reactions with consumer call transfer to the AME Line, when indicated. 	\$379,469		Australian Government Department of Health
	Schedule 10B	Adverse Medicine Event Line	<p>To provide consumers with an avenue for reporting and discussing adverse experiences with medicines and provide independent, accurate and evidence-based information and improve health outcomes for consumers.</p> <p>Reporting of consumer-mediated Adverse Drug Reaction reports to the TGA to support national pharmacovigilance initiatives.</p> <p>To improve consumer knowledge of quality use of medicines and other health technologies and promote medication safety.</p>	<ul style="list-style-type: none"> To increase consumer knowledge around safe and appropriate use of medicines. To assist the TGA with reporting of consumer mediated Adverse Drug Reactions. Provision of a communications and reporting service to increase awareness of QUM principles and practices for consumers. 	\$195,721		Australian Government Department of Health